A Phase 2/3 clinical trial, ARTISTS 1, evaluating Teva Pharmaceutical Industries’ (NYSE:TEVA) deutetrabenazine for the treatment of tics in pediatric patients with moderate-to-severe Tourette syndrome failed to achieve the primary endpoint.
Deutetrabenazine to not sufficiently separate from placebo as measured by the change in Total Tic Score from baseline at week 12.
The company markets the drug as Austedo for the treatment of Huntington’s disease chorea and tardive dyskinesia.
Shares down 5% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.